Compare FNWD & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | FNWD | MOLN |
|---|---|---|
| Founded | 1994 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Savings Institutions | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.0M | 158.9M |
| IPO Year | N/A | 2021 |
| Metric | FNWD | MOLN |
|---|---|---|
| Price | $37.47 | $4.61 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $34.00 | $8.38 |
| AVG Volume (30 Days) | ★ 18.5K | 5.9K |
| Earning Date | 01-27-2026 | 03-13-2026 |
| Dividend Yield | ★ 1.30% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.88 | N/A |
| Revenue | ★ $66,245,999.00 | N/A |
| Revenue This Year | $16.40 | N/A |
| Revenue Next Year | $5.36 | $999.99 |
| P/E Ratio | $19.66 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $26.16 | $3.36 |
| 52 Week High | $39.99 | $5.10 |
| Indicator | FNWD | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 52.69 | 60.72 |
| Support Level | $36.97 | $4.33 |
| Resistance Level | $38.99 | $4.74 |
| Average True Range (ATR) | 0.84 | 0.20 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 64.78 | 86.75 |
Finward Bancorp is a bank holding company, which engages in the provision of financial services. It offers products and services related to Personal Banking, Cash Management, Saving Account, ebanking, Wealth Management, and Insurance Services. It is engaged in the business of attracting deposits from the general public and the origination of loans, mostly upon the security of single-family residences and commercial real estate, construction loans, commercial business loans, and municipal loans. Geographically, the activities are carried out through the United States.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.